MedTrace Logo

PPMI Clinical - Establishing a Deeply Phenotyped PD Cohort

NCT04477785 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 4500

Last updated 2026-03-27

No results posted yet for this study

Summary

The Parkinson Progression Marker Initiative (PPMI) is a longitudinal, observational, multi-center natural history study to assess progression of clinical features, digital outcomes, and imaging, biologic and genetic markers of Parkinson's disease (PD) progression in study participants with manifest PD, prodromal PD, and healthy controls.

The overall goal of PPMI is to identify markers of disease progression for use in clinical trials of therapies to reduce progression of PD disability.

Conditions

  • Parkinson Disease

Sponsors & Collaborators

  • Institute for Neurodegenerative Disorders

    collaborator OTHER

  • Michael J. Fox Foundation for Parkinson's Research

    lead OTHER

Principal Investigators

  • Kenneth L Marek, MD · Institute for Neurodegenerative Disorders

  • Caroline Tanner, MD, PhD · University of California, San Francisco

Eligibility

Min Age
30 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2020-07-01
Primary Completion
2033-12-31
Completion
2033-12-31

Countries

  • United States
  • Austria
  • Canada
  • Germany
  • Greece
  • Israel
  • Italy
  • Luxembourg
  • Netherlands
  • Nigeria
  • Spain
  • United Kingdom

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04477785 on ClinicalTrials.gov